{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:42:18Z","timestamp":1793356938187,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J01234"],"award-info":[{"award-number":["2025J01234"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s11604-026-02060-z","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:47:53Z","timestamp":1787730473000},"page":"2050-2060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic body radiation therapy for hepatocellular carcinoma larger than 5\u00a0cm: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Jiaoling","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiurong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingfang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-229X","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2060_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel L R, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74:229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"2060_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/JHC.S433409","volume":"10","author":"Y Yang","year":"2023","unstructured":"Yang Y, Du N, Ma J, Peng Z, Zhou B, Yu J, et al. Efficacy and safety of transarterial chemoembolization with a three-stage mixed chemoembolic regimen for large unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1897\u2013910.","journal-title":"J Hepatocell Carcinoma"},{"key":"2060_CR3","first-page":"791","volume":"9","author":"H Yuan","year":"2019","unstructured":"Yuan H, Lan Y, Li X, Tang J, Liu F. Large hepatocellular carcinoma with local remnants after transarterial chemoembolization: treatment by sorafenib combined with radiofrequency ablation or sorafenib alone. Am J Cancer Res. 2019;9:791\u20139.","journal-title":"Am J Cancer Res"},{"key":"2060_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/CMAR.S481242","volume":"17","author":"Y Wu","year":"2025","unstructured":"Wu Y, Zhu J, Zhang H, Xia N. The combination of D-TACE-HAIC, lenvatinib, and PD-1 inhibitors shows significant clinical efficacy in patients with unresectable hepatocellular carcinoma. Cancer Manag Res. 2025;17:239\u201347.","journal-title":"Cancer Manag Res"},{"key":"2060_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","volume":"118","author":"SH Bae","year":"2024","unstructured":"Bae SH, Chun SJ, Chung JH, Kim E, Kang J, Jang W. Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and international stereotactic radiosurgery society practice guidelines. Int J Radiat Oncol Biol Phys. 2024;118:337\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2060_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Sunil K, Guha C. Stereotactic Body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial. JAMA Oncol. 2025;11:136\u201344.","journal-title":"JAMA Oncol"},{"key":"2060_CR7","doi-asserted-by":"crossref","unstructured":"Wei X, Jiang Y, Li Y, Shi H, Guo W, Shi J et al. Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study. Oncologist. 2026;31.","DOI":"10.1093\/oncolo\/oyaf437"},{"key":"2060_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO-24-01532","volume":"43","author":"M Xi","year":"2025","unstructured":"Xi M, Yang Z, Hu L, Fu Y, Hu D, Zhou Z, et al. Radiofrequency Ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: a randomized, open-label, controlled trial. J Clin Oncol. 2025;43:1073\u201382.","journal-title":"J Clin Oncol"},{"key":"2060_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1748-717X-9-120","volume":"9","author":"JY Que","year":"2014","unstructured":"Que JY, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol. 2014;9:120.","journal-title":"Radiat Oncol"},{"key":"2060_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/030089161009600111","volume":"96","author":"YJ Shin","year":"2010","unstructured":"Shin YJ, Kim MS, Yoo SY, Cho CK, Seo YS, Kang JK, et al. Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori. 2010;96:65\u201370.","journal-title":"Tumori"},{"key":"2060_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1186\/s12885-016-2894-9","volume":"16","author":"TS Su","year":"2016","unstructured":"Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao Y, et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma\u2009>\u20095\u00a0cm. BMC Cancer. 2016;16:834.","journal-title":"BMC Cancer"},{"key":"2060_CR12","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"2060_CR13","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18:2127\u201333.","journal-title":"JBI Evid Synth"},{"key":"2060_CR14","doi-asserted-by":"publisher","first-page":"105247","DOI":"10.1016\/j.critrevonc.2026.105247","volume":"222","author":"P Sun","year":"2026","unstructured":"Sun P, Yang H, Li B, Wang Y, Liu P, Li Z. Efficacy of zanubrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol\/Hematol. 2026;222:105247.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"2060_CR15","doi-asserted-by":"crossref","unstructured":"Liang Y, Yang J, Li H, Wu J, Tan W, Ren Y et al. Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study. Int J Surg. 2026;112.","DOI":"10.1097\/JS9.0000000000004131"},{"key":"2060_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.21037\/hbsn-21-423","volume":"12","author":"XF Xu","year":"2023","unstructured":"Xu XF, Wu H, Li JD, Yao LQ, Huang B, Diao YK, et al. Association of tumor morphology with long-term prognosis after liver resection for patients with a solitary huge hepatocellular carcinoma-a multicenter propensity score matching analysis. Hepatobiliary Surg Nutr. 2023;12:314\u201327.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2060_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clon.2020.01.028","volume":"32","author":"L Beaton","year":"2020","unstructured":"Beaton L, Dunne EM, Yeung R, Rackley T, Weber B, Mar C, et al. Stereotactic body radiotherapy for large unresectable hepatocellular carcinomas - a single institution phase II study. Clin Oncol (R Coll Radiol). 2020;32:423\u201332.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2060_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00066-018-1391-2","volume":"195","author":"CL Chiang","year":"2019","unstructured":"Chiang CL, Chan MKH, Yeung CSY, Ho CHM, LEE F A S, et al. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol. 2019;195:254\u201364.","journal-title":"Strahlenther Onkol"},{"key":"2060_CR19","doi-asserted-by":"publisher","first-page":"20181053","DOI":"10.1259\/bjr.20181053","volume":"92","author":"S Chopra","year":"2019","unstructured":"Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K, et al. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol. 2019;92:20181053.","journal-title":"Br J Radiol"},{"key":"2060_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3892\/mco.2017.1255","volume":"6","author":"YZ Dang","year":"2017","unstructured":"Dang YZ, Li X, Huang SG, Lu WL, Wang G, Zhang D, et al. Curative effect of stereotactic body radiotherapy for unresectable massive primary liver cancer. Mol Clin Oncol. 2017;6:911\u20136.","journal-title":"Mol Clin Oncol"},{"key":"2060_CR21","doi-asserted-by":"publisher","first-page":"e9249","DOI":"10.1097\/MD.0000000000009249","volume":"96","author":"HT Kuo","year":"2017","unstructured":"Kuo HT, Que J, Lin LC, Yang CC, Koay LB, Lin CH, et al. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Med (Baltim). 2017;96:e9249.","journal-title":"Med (Baltim)"},{"key":"2060_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/jcrt.jcrt_1118_24","volume":"21","author":"D Sharma","year":"2025","unstructured":"Sharma D, Meena BL, Anju KV, Jagya D, Sarin SK, Yadav HP. Efficacy and safety of stereotactic body radiation therapy in elderly patients with cirrhosis and large advanced hepatocellular carcinoma. J Cancer Res Ther. 2025;21:137\u201344.","journal-title":"J Cancer Res Ther"},{"key":"2060_CR23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5603\/RPOR.a2021.0016","volume":"26","author":"R Kumar","year":"2021","unstructured":"Kumar R, Yadav HP, Thaper D, Kamal R, Gupta A, Kirti S. Efficacy and toxicity of SBRT in advanced hepatocellular carcinoma with portal vein tumor thrombosis - a retrospective study. Rep Pract Oncol Radiother. 2021;26:573\u201381.","journal-title":"Rep Pract Oncol Radiother"},{"key":"2060_CR24","doi-asserted-by":"publisher","first-page":"8298","DOI":"10.12659\/MSM.910735","volume":"24","author":"L Wang","year":"2018","unstructured":"Wang L, Li L, Wang X, Zhao D, Shan G, Wu X, et al. Comparison of combination stereotactic body radiotherapy plus high-intensity focused ultrasound ablation versus stereotactic body radiotherapy alone for massive hepatocellular carcinoma. Med Sci Monit. 2018;24:8298\u2013305.","journal-title":"Med Sci Monit"},{"key":"2060_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3857\/roj.2017.00598","volume":"36","author":"KH Lee","year":"2018","unstructured":"Lee KH, Yu JI, Park HC, Park SY, Shin JS, Shin EH, et al. Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma? Radiat Oncol J. 2018;36:129\u201338.","journal-title":"Radiat Oncol J"},{"key":"2060_CR26","doi-asserted-by":"publisher","first-page":"116675","DOI":"10.1016\/j.ejca.2026.116675","volume":"238","author":"Y Fu","year":"2026","unstructured":"Fu Y, Liu S, Chen J, Zhang L, Wang J, Pan Y, et al. Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: a post-hoc analysis with propensity score adjustment from two randomized trials. Eur J Cancer. 2026;238:116675.","journal-title":"Eur J Cancer"},{"key":"2060_CR27","first-page":"45","volume":"20","author":"END Kok","year":"2020","unstructured":"Kok END, Jansen EPM, Heeres BC, Kok NFM, Janssen T, Werkhoven EV, et al. High versus low dose stereotactic body radiation therapy for hepatic metastases. Clin Transl Radiat Oncol. 2020;20:45\u201350.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2060_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13014-021-01778-6","volume":"16","author":"T Su","year":"2021","unstructured":"Su T, Liu Q, Zhu X, Liang P, Liang X, Lai L, et al. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. Radiat Oncol. 2021;16:79.","journal-title":"Radiat Oncol"},{"key":"2060_CR29","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00432-018-2729-y","volume":"144","author":"S Lazarev","year":"2018","unstructured":"Lazarev S, Hardy-Abeloos C, Factor O, Rosenzweig K, Buckstein M. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities. J Cancer Res Clin Oncol. 2018;144:2077\u201383.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2060_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13014-017-0851-7","volume":"12","author":"E Gkika","year":"2017","unstructured":"Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. 2017;12:116.","journal-title":"Radiat Oncol"},{"key":"2060_CR31","doi-asserted-by":"crossref","unstructured":"Leung HWC, Wang SY, Leung JH, Tai YS, Chan ALF. Efficacy and safety of stereotactic body radiation therapy modalities for >\u20095\u00a0cm advanced unresectable hepatocellular carcinoma: a network meta-analysis. Cancers (Basel). 2026;18.","DOI":"10.3390\/cancers18060988"},{"key":"2060_CR32","doi-asserted-by":"crossref","unstructured":"Hatanaka T, Shibuya K, Kakizaki S, Hiraoka A, Tada T, Kariyama K et al. Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma. Hepatol Commun. 2025;9.","DOI":"10.1097\/HC9.0000000000000801"},{"key":"2060_CR33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3350\/cmh.2023.0217","volume":"29","author":"HK Byun","year":"2023","unstructured":"Byun HK, Kim C, Seong J. Carbon ion radiotherapy in the treatment of hepatocellular carcinoma. Clin Mol Hepatol. 2023;29:945\u201357.","journal-title":"Clin Mol Hepatol"},{"key":"2060_CR34","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ijrobp.2004.01.032","volume":"59","author":"H Kato","year":"2004","unstructured":"Kato H, Tsujii H, Miyamoto T, Mizoe J, Kamada T, Tsuji H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys. 2004;59:1468\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2060_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.semradonc.2018.06.008","volume":"28","author":"S Apisarnthanarax","year":"2018","unstructured":"Apisarnthanarax S, Bowen SR, Combs SE. Proton beam therapy and carbon ion radiotherapy for hepatocellular carcinoma. Semin Radiat Oncol. 2018;28:309\u201320.","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"2060_CR36","doi-asserted-by":"publisher","first-page":"e71639","DOI":"10.1002\/cam4.71639","volume":"15","author":"M Mizumoto","year":"2026","unstructured":"Mizumoto M, Shibuya K, Terashima K, Iwata H, Saito T, Toyama S, et al. Prospective registry and meta-analysis of particle therapy for hepatocellular carcinoma: clinical outcomes and real-world impact. Cancer Med. 2026;15(3):e71639.","journal-title":"Cancer Med"},{"key":"2060_CR37","doi-asserted-by":"crossref","unstructured":"Hayashi K, Suzuki O, Ichise K, Uchida H, Nagano F, Hasegawa A et al. Efficacy and safety of carbon-ion radiotherapy for large hepatocellular carcinoma (diameter\u2009\u2265\u200910\u00a0cm). BMC Cancer. 2026.","DOI":"10.21203\/rs.3.rs-8942237\/v1"},{"key":"2060_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/jrr\/rry056","volume":"59","author":"M Nakamura","year":"2018","unstructured":"Nakamura M, Fukumitsu N, Kamizawa S, Numajiri H, Nemoto Murofushi K, Ohnishi K, et al. A validated proton beam therapy patch-field protocol for effective treatment of large hepatocellular carcinoma. J Radiat Res. 2018;59:632\u20138.","journal-title":"J Radiat Res"},{"key":"2060_CR39","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ijrobp.2023.09.049","volume":"118","author":"RC Hsieh","year":"2024","unstructured":"Hsieh RC, Lee CH, Huang HC, Wu SW, Chou CY, Hung SP, et al. Clinical and dosimetric results of proton or photon radiation therapy for large (>\u20095 cm) hepatocellular carcinoma: a retrospective analysis. Int J Radiat Oncol Biol Phys. 2024;118:712\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2060_CR40","first-page":"100605","volume":"40","author":"S Tubin","year":"2023","unstructured":"Tubin S, Vozenin MC, Prezado Y, Durante M, Prise KM, Lara PC, et al. Novel unconventional radiotherapy techniques: current status and future perspectives - Report from the 2nd international radiation oncology online seminar. Clin Transl Radiat Oncol. 2023;40:100605.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2060_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13014-025-02691-y","volume":"20","author":"KL McCarty","year":"2025","unstructured":"McCarty KL, Watt T, Dan TD, Timmerman RD, Kumar KA. Use of PULSAR (personalized ultra-fractionated stereotactic adaptive radiotherapy) as consolidation with immune checkpoint inhibition in the treatment of pediatric metastatic melanoma. Radiat Oncol. 2025;20:132.","journal-title":"Radiat Oncol"},{"key":"2060_CR42","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2021.03.047","volume":"110","author":"C Moore","year":"2021","unstructured":"Moore C, Hsu CC, Chen WM, Chen BPC, Han C, Story M, et al. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade. Int J Radiat Oncol Biol Phys. 2021;110:1306\u201316.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2060_CR43","doi-asserted-by":"crossref","unstructured":"Westover KD, Li R, Tanner S, Aliru M, Lin MH, Cai B et al. Personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) for patients with lung tumors and severe pulmonary disease. J Clin Med. 2026;15.","DOI":"10.3390\/jcm15031261"},{"key":"2060_CR44","doi-asserted-by":"publisher","first-page":"1497351","DOI":"10.3389\/fonc.2024.1497351","volume":"14","author":"H Peng","year":"2024","unstructured":"Peng H, Moore C, Saha D, Jiang S, Timmerman R. Understanding the PULSAR effect in combined radiotherapy and immunotherapy using transformer-based attention mechanisms. Front Oncol. 2024;14:1497351.","journal-title":"Front Oncol"},{"key":"2060_CR45","doi-asserted-by":"publisher","first-page":"1357790","DOI":"10.3389\/fonc.2024.1357790","volume":"14","author":"H Peng","year":"2024","unstructured":"Peng H, Deng J, Jiang S, Timmerman R. Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy. Front Oncol. 2024;14:1357790.","journal-title":"Front Oncol"},{"key":"2060_CR46","first-page":"945","volume":"38","author":"K Uemoto","year":"2018","unstructured":"Uemoto K, Doi H, Shiomi H, Yamada K, Tatsumi D, Yasumoto T, et al. Clinical assessment of micro-residual tumors during stereotactic body radiation therapy for hepatocellular carcinoma. Anticancer Res. 2018;38:945.","journal-title":"Anticancer Res"},{"key":"2060_CR47","doi-asserted-by":"publisher","first-page":"1427332","DOI":"10.3389\/fonc.2024.1427332","volume":"14","author":"E Gkika","year":"2024","unstructured":"Gkika E, Radicioni G, Eichhorst A, Kirste S, Sprave T, Nicolay NH, et al. The role of ALBI score in patients treated with stereotactic body radiotherapy for locally advanced primary liver tumors: a pooled analysis of two prospective studies. Front Oncol. 2024;14:1427332.","journal-title":"Front Oncol"},{"key":"2060_CR48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jrr\/rrae006","volume":"65","author":"Y Yoshino","year":"2024","unstructured":"Yoshino Y, Suzuki G, Shiomi H, Kimoto T, Seri S, Yamazaki H, et al. Albumin-bilirubin score is a useful predictor of worsening liver reserve after stereotactic body radiation therapy in elderly Japanese patients with hepatocellular carcinoma. J Radiat Res. 2024;65:244\u201350.","journal-title":"J Radiat Res"},{"key":"2060_CR49","doi-asserted-by":"publisher","first-page":"102555","DOI":"10.1016\/j.jceh.2025.102555","volume":"15","author":"D Sharma","year":"2025","unstructured":"Sharma D, Meena BL, Yadav HP, Kumar G, Jagya VAK. Predictive factors and nomogram (MAP-BNP) for post stereotactic body radiotherapy survival in advanced hepatocellular carcinoma patients. J Clin Exp Hepatol. 2025;15:102555.","journal-title":"J Clin Exp Hepatol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02060-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:15:28Z","timestamp":1793355328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02060-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2060"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02060-z","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not involve human participants.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}